Bayer has officially opened its new life science incubator, Bayer Co.Lab Shanghai, located in the Shanghai Innovation (SH-INNO) Park within China’s largest biopharma hub, Zhangjiang, Shanghai. This marks a significant step in Bayer’s global innovation strategy, with Co.Lab Shanghai joining a network of life science incubators in key innovation centers, including Cambridge (USA), Kobe (Japan), and Berlin (Germany). The incubator is designed to foster collaboration in the biotech ecosystem, providing state-of-the-art laboratories, collaborative spaces, and tailored support for startups across the biopharmaceutical value chain.
“Shanghai’s dynamic innovation ecosystem, supported by universities, startups, incubators, and investors, makes it an ideal location,” said Juergen Eckhardt, MD, Head of Business Development & Licensing at Bayer Pharmaceuticals. “Bayer Co.Lab Shanghai offers startups access to our expertise in cell and gene therapy and oncology, connecting them to our global innovation and partner networks, helping them grow and thrive.”
China, home to the world’s second-largest pharmaceutical market, has become a global leader in pharmaceutical innovation. Bayer, with over 140 years of presence in China, has expanded its R&D footprint by establishing two global R&D centers and four world-class production facilities in the country. Additionally, China plays a vital role in Bayer’s global clinical trials, with over 80% of its major multi-center trials conducted there. Collaborations with top academic institutions like Tsinghua University and Peking University have resulted in over 100 joint research projects, positioning Bayer as a leader in collaborative pharmaceutical innovation.
The opening of Bayer Co.Lab Shanghai reinforces the company’s commitment to driving innovation in China and globally. By deepening local partnerships and accelerating co-creation, Bayer aims to push the boundaries of healthcare innovation.
Looking ahead, Bayer will open Bayer Co.Lab Berlin in November 2024 at its global Pharmaceuticals division headquarters, focusing on cutting-edge cell and gene therapies and other advanced modalities.
